v45q8ig6

Property	Value
?:abstract	Background: There are currently no effective treatments for outpatients with coronavirus disease 2019 (COVID-19). Interferon-lambda-1 is a Type III interferon involved in the innate antiviral response with activity against respiratory pathogens. Methods: In this double-blind, placebo-controlled trial, outpatients with laboratory-confirmed COVID-19 were randomized to a single subcutaneous injection of peginterferon-lambda 180mcg or placebo within 7 days of symptom onset or first positive swab if asymptomatic. The primary endpoint was proportion negative for SARS-CoV-2 RNA on Day 7 post-injection. Findings: There were 30 patients per arm, with median baseline SARS-CoV-2 viral load of 6.71 (IQR 1.3-8.0) log copies/mL. The decline in SARS-CoV-2 RNA was greater in those treated with peginterferon-lambda than placebo (p=0.04). On Day 7, 24 participants (80%) in the peginterferon-lambda group had an undetectable viral load compared to 19 (63%) in the placebo arm (p=0.15). After controlling for baseline viral load, peginterferon lambda treatment resulted in a 4.12-fold (95CI 1.15-16.7, p=0.029) higher likelihood of viral clearance by Day 7. Of those with baseline viral load above 10E6 copies/mL, 15/19 (79%) in the peginterferon-lambda group were undetectable on Day 7 compared to 6/16 (38%) in the placebo group (p=0.012). Adverse events were similar between groups with only mild reversible transaminase elevations more frequently observed in the peginterferon-lambda group. Interpretation: Peginterferon-lambda accelerated viral decline in outpatients with COVID-19 resulting in a greater proportion with viral clearance by Day 7, particularly in those with high baseline viral load. Peginterferon-lambda may have potential to prevent clinical deterioration and shorten duration of viral shedding. (NCT04354259)
is ?:annotates of	<https://research.tib.eu/covid-19/entity/v45q8ig6_hasAnnotation_C0035668> <https://research.tib.eu/covid-19/entity/v45q8ig6_hasAnnotation_C0162633> <https://research.tib.eu/covid-19/entity/v45q8ig6_hasAnnotation_C0877248> <https://research.tib.eu/covid-19/entity/v45q8ig6_hasAnnotation_C1425473> <https://research.tib.eu/covid-19/entity/v45q8ig6_hasAnnotation_C1825561> <https://research.tib.eu/covid-19/entity/v45q8ig6_hasAnnotation_C3715044> <https://research.tib.eu/covid-19/entity/v45q8ig6_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Feld%2C_J._J.%3B_Kandel%2C_C.%3B_Biondi%2C_M._J.%3B_Kozak%2C_R._A.%3B_Zahoor%2C_M._A.%3B_Lemieux%2C_C.%3B_Borgia%2C_S._M.%3B_Boggild%2C_A._K.%3B_Powis%2C_J.%3B_McCready%2C_J.%3B_Tan%2C_D._H.%3B_Chan%2C_T.%3B_Coburn%2C_B.%3B_Kumar%2C_D.%3B_Humar%2C_A.%3B_Chan%2C_A.%3B_O%27Neil%2C_B.%3B_Noureldin%2C_S.%3B_Booth%2C_J.%3B_Hong%2C_R.%3B_Smookler%2C_D.%3B_Aleyadeh%2C_W.%3B_Patel%2C_A.%3B_Barber%2C_B.%3B_Casey%2C_J.%3B_Hiebert%2C_R.%3B_Mistry%2C_H.%3B_Choong%2C_I.%3B_Hislop%2C_C.%3B_Santer%2C_D.%3B_Tyrrell%2C_D._L.%3B_Glenn%2C_J._S.%3B_Gehring%2C_A._J.%3B_Janssen%2C_H._L.%3B_Hansen%2C_B.>
?:doi	10.1101/2020.11.09.20228098
?:doi	<https://research.tib.eu/covid-19/entity/10.1101/2020.11.09.20228098>
?:license	medrxiv
?:pdf_json_files	document_parses/pdf_json/2bc0f5ef26b31014fe164ec61c2cfe91548f1860.json
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/2bc0f5ef26b31014fe164ec61c2cfe91548f1860>
?:source	MedRxiv; WHO
?:title	Peginterferon-lambda for the treatment of COVID-19 in outpatients
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-12

Property

Value

?:abstract

Background: There are currently no effective treatments for outpatients with coronavirus disease 2019 (COVID-19). Interferon-lambda-1 is a Type III interferon involved in the innate antiviral response with activity against respiratory pathogens. Methods: In this double-blind, placebo-controlled trial, outpatients with laboratory-confirmed COVID-19 were randomized to a single subcutaneous injection of peginterferon-lambda 180mcg or placebo within 7 days of symptom onset or first positive swab if asymptomatic. The primary endpoint was proportion negative for SARS-CoV-2 RNA on Day 7 post-injection. Findings: There were 30 patients per arm, with median baseline SARS-CoV-2 viral load of 6.71 (IQR 1.3-8.0) log copies/mL. The decline in SARS-CoV-2 RNA was greater in those treated with peginterferon-lambda than placebo (p=0.04). On Day 7, 24 participants (80%) in the peginterferon-lambda group had an undetectable viral load compared to 19 (63%) in the placebo arm (p=0.15). After controlling for baseline viral load, peginterferon lambda treatment resulted in a 4.12-fold (95CI 1.15-16.7, p=0.029) higher likelihood of viral clearance by Day 7. Of those with baseline viral load above 10E6 copies/mL, 15/19 (79%) in the peginterferon-lambda group were undetectable on Day 7 compared to 6/16 (38%) in the placebo group (p=0.012). Adverse events were similar between groups with only mild reversible transaminase elevations more frequently observed in the peginterferon-lambda group. Interpretation: Peginterferon-lambda accelerated viral decline in outpatients with COVID-19 resulting in a greater proportion with viral clearance by Day 7, particularly in those with high baseline viral load. Peginterferon-lambda may have potential to prevent clinical deterioration and shorten duration of viral shedding. (NCT04354259)

is ?:annotates of